

# Human T-Cell Leukemia Virus Type I Tax Activates Transcription of the Human Monocyte Chemoattractant Protein-1 Gene through Two Nuclear Factor- $\kappa$ B Sites

Naoki Mori,<sup>1</sup> Atsuhisa Ueda, Shuichi Ikeda, Yoshihiro Yamasaki, Yasuaki Yamada, Masao Tomonaga, Shigeru Morikawa, Romas Geleziunas, Teizo Yoshimura, and Naoki Yamamoto

Department of Preventive Medicine and AIDS Research, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan [N. M., N. Y.]; Department of Laboratory Medicine, Nagasaki University School of Medicine, Nagasaki 852-8501, Japan [Y. Yamad.]; Department of Hematology, Atomic Disease Institute, Nagasaki University School of Medicine, Nagasaki 852-8523, Japan [M. T.]; Department of Internal Medicine, City of Sasebo General Hospital, Sasebo 857-8511, Japan [S. I.]; Department of Internal Medicine, Kokura Memorial Hospital, Kitakyushu 802-8555, Japan [Y. Yamas.]; Department of Pathology First Unit, Shimane Medical University, Izumo 693-8501, Japan [S. M.]; First Department of Internal Medicine, Yokohama City University School of Medicine, Yokohama 236-0004, Japan [A. U.]; Gladstone Institute of Virology and Immunology, San Francisco, California 94141-9100 [R. G.]; and Immunopathology Section, Laboratory of Immunobiology, National Cancer Institute-Frederick Cancer Research and Development Center, Frederick, Maryland 21702 [T. Y.]

## ABSTRACT

Infection by human T-cell leukemia virus type (HTLV) I leads to adult T-cell leukemia and is also associated with the neurodegenerative disease HTLV-I-associated myelopathy/tropical spastic paraparesis. Leukocytes are attracted to sites of inflammation by chemokines. One such chemokine is monocyte chemoattractant protein (MCP)-1, a member of the C-C subfamily of chemokines. We investigated whether HTLV-I infection causes up-regulation of MCP-1, which may in turn cause recruitment of leukocytes to HTLV-I-infected areas. We now report that MCP-1 mRNA levels are elevated in HTLV-I-infected T-cell lines, when compared with uninfected ones. We further confirmed secretion of MCP-1 by HTLV-I-infected T-cell lines. MCP-1 mRNA was also expressed in leukemic cells from patients with adult T-cell leukemia. The 5' transcriptional regulatory region of the MCP-1 gene was activated by the HTLV-I-encoded transactivator Tax in the human T-cell line Jurkat, in which endogenous MCP-1 is induced by Tax. By using site-specific point mutations, we have identified two closely spaced nuclear factor (NF)- $\kappa$ B sites, A1 and A2, to be important for Tax-mediated transactivation of the MCP-1 gene. Through the use of an electrophoretic mobility shift assay, we demonstrated that Tax induced NF- $\kappa$ B binding to both MCP-1  $\kappa$ B sites. This is the first report to demonstrate that Tax can transactivate the MCP-1 gene through the induction of NF- $\kappa$ B. Our results thus reveal how Tax disrupts the normally regulated MCP-1 gene and leads to its constitutive expression in HTLV-I-infected cells. These findings may have important implications for our understanding of HTLV-I-associated diseases.

## INTRODUCTION

HTLV-I<sup>2</sup> is the etiological agent of ATL (1, 2). HTLV-I may also be associated with several chronic inflammatory diseases of presumed autoimmune etiology, such as HAM/TSP (3, 4), HTLV-I-associated arthropathy (5), uveitis (6), and Sjögren's syndrome (7). A characteristic feature of these HTLV-I-associated diseases is infiltration of lymphocytes, including virus-infected cells, into affected tissues. The possible roles of abnormal immune activation, adhesion molecules, and cytokine or chemokine overproduction in the pathogenesis of diseases caused by HTLV-I have been suggested, but the mechanism by which they cause these diseases remains unknown.

Chemokines are thought to play a major role in the migration of cells from one tissue to another, thereby controlling cell migration

during inflammation. MCP-1 is a member of the C-C chemokine family (8, 9). MCP-1 and other chemokines are typically expressed in tissues during inflammation and are induced in a variety of cell types *in vitro* by the proinflammatory mediators tumor necrosis factor- $\alpha$ , IL-1, and endotoxins (9, 10). MCP-1 appears to be important for activation of leukocyte subsets and triggers their adhesiveness and transmigration through the endothelial layer. Inhibition of induced MCP-1 expression is associated with reduced transmigration of monocytes (11) as well as with diminished recruitment of T cells (12). Accordingly, neutralizing antibodies against MCP-1 have been shown to inhibit T-cell recruitment and cutaneous delayed-type hypersensitivity (13), thus suggesting the importance of MCP-1 at the onset of inflammatory processes.

Recent studies revealed that MCP-1 was expressed on perivascular infiltrating cells as well as on vascular endothelium in the spinal cord lesions of HAM/TSP patients (14). These findings suggest that MCP-1 may play a pathological role in HTLV-I-associated diseases. However, little is known about the molecular mechanisms of constitutive MCP-1 expression in HTLV-I-infected T cells. The virally encoded transcriptional activator Tax has multiple functions. Tax has been shown to transform cell lines and primary T cells *in vitro*, whereas transgenic mice expressing Tax develop nonlymphoid tumors, leukemia, and various inflammatory diseases *in vivo*. Tax activates the transcription of not only the HTLV-I LTR but also of a number of cellular genes *in trans*. This transactivation by Tax is mediated through interaction with transcription factors such as cyclic AMP-responsive element binding protein (15) in the case of the HTLV-I LTR, NF- $\kappa$ B (16), and serum-responsive factor (CARG box binding protein; Ref. 17). To activate NF- $\kappa$ B, Tax has been suggested to target certain cellular kinases that induce IKKs, NIK, and mitogen-activated protein/extracellular signal-regulated kinase kinase 1 (18–24). In the present study, we report that Tax is capable of inducing the MCP-1 chemokine gene in T cells. Furthermore, we analyzed the mechanism of Tax-induced transcriptional regulation of MCP-1. We demonstrate that the activation of NF- $\kappa$ B is required for Tax activation of MCP-1. Tax-induced MCP-1 transactivation was mediated through two NF- $\kappa$ B binding sites located ~2.6 kb from the transcription initiation site.

## MATERIALS AND METHODS

**Cell Lines.** Human T-cell lines, Jurkat, MOLT-4, and CCRF-CEM, and HTLV-I-infected T-cell lines OMT (25), C5/MJ (26), MT-2 (27), and HPB-ATL-O were grown in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum, 50 units/ml penicillin G, and 50  $\mu$ g/ml streptomycin in a humidified incubator containing 5% CO<sub>2</sub>. JPX-9 and JPX-9/M (kindly provided by Dr. M. Nakamura, Tokyo Medical and Dental University, Tokyo, Japan) is a subclone of Jurkat cells expressing Tax and nonfunctional Tax mutant under the control of the metallothionein promoter (28, 29).

Received 2/28/00; accepted 6/20/00.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

<sup>1</sup> To whom requests for reprints should be addressed, at Department of Preventive Medicine and AIDS Research, Institute of Tropical Medicine, Nagasaki University, 1-12-4, Sakamoto, Nagasaki 852-8523, Japan. Phone: 81-95-849-7846; Fax: 81-95-849-7805; E-mail: n-mori@net.nagasaki-u.ac.jp.

<sup>2</sup> The abbreviations used are: HTLV-I, human T-cell leukemia virus type I; ATL, adult T-cell leukemia; HAM/TSP, HTLV-I-associated myelopathy/tropical spastic paraparesis; MCP-1, monocyte chemoattractant protein-1; IL, interleukin; LTR, long terminal repeat; LUC, luciferase; NF, nuclear factor; IKK, I $\kappa$ B kinase; NIK, NF- $\kappa$ B-inducing kinase; RT-PCR, reverse transcription-PCR; R, receptor; EMSA, electrophoretic mobility shift assay; PBMC, peripheral blood mononuclear cell.

**Patient Samples.** The study protocol was approved by the Human Ethics Review Committees of the participating institutions. Leukemic cells from six patients diagnosed with acute-type ( $n = 3$ ; patients 2, 4, and 6) and chronic-type ATL ( $n = 3$ ; patients 1, 3, and 5) were analyzed. The diagnosis was based on clinical features, hematological findings, and serum anti-HTLV-I antibodies. Monoclonal HTLV-I provirus integration into the DNA of leukemic cells was confirmed by Southern blot hybridization in all cases (data not shown). Mononuclear cells were isolated by Ficoll/Hypaque (Pharmacia LKB, Uppsala, Sweden) density gradient centrifugation and washed with PBS.

**RT-PCR.** Total RNA was extracted with Trizol (Life Technologies, Inc., Gaithersburg, MD) according to the protocol provided by the manufacturer. First-strand cDNA was synthesized in a 20- $\mu$ l reaction volume using an RNA-PCR kit (Takara Shuzo, Kyoto, Japan) with random primers. Thereafter, cDNA was amplified for 35 and 28 cycles for MCP-1 and  $\beta$ -actin, respectively. The oligonucleotide primers used were as follows: for MCP-1: sense, 5'-TCGCTCAGCCAGATGCAATCAATGC-3' and antisense, 5'-CCCAGGGGTAGAACTGTGGTTCAA-3' (30); and for  $\beta$ -actin: sense, 5'-GTGGGGCGCCAGGCACCA-3' and antisense, 5'-CTCCTTAATGT-CACGCACGATTTC-3'. Product sizes were 479 bp for MCP-1 and 548 bp for  $\beta$ -actin. Cycling conditions were as follows: denaturing at 94°C (30 s), annealing at 60°C (30 s), and extension at 72°C (60 s for MCP-1 and 90 s for  $\beta$ -actin). The PCR products were fractionated on 2% agarose gels and visualized by ethidium bromide staining.

**Northern Blot Analysis.** Total RNA (20  $\mu$ g) was electrophoresed through a formaldehyde-agarose gel and transferred onto a nylon filter. Filters were prehybridized (in 0.5 M sodium phosphate, 0.1% BSA, 7% SDS, 100  $\mu$ g/ml salmon testis DNA, and 100  $\mu$ g/ml yeast RNA) for 2 h at 65°C and then hybridized overnight with the following:  $\alpha$ -<sup>32</sup>P-radiolabeled probes: cDNA of HTLV-I Tax (31) and glyceraldehyde-3-phosphate dehydrogenase (32). Radiolabeled probes were generated using a Megaprime DNA Labeling system (Amersham, Arlington Heights, IL).

**ELISA for MCP-1.** Cells were suspended in fresh culture medium at a concentration of  $5 \times 10^5$  cells/ml and cultured for 72 h. After centrifugation, MCP-1 concentrations were measured in the culture supernatants using a commercially available ELISA kit (Biosource International, Inc., Camarillo, CA).

**Plasmids.** The LUC reporter constructs contained the proximal promoter region and distal enhancer region of the human *MCP-1* gene and have recently been described in detail (33). The HTLV-I LTR-LUC reporter was generated by introducing the full-length HTLV-I LTR into the pGL2-Basic vector (Promega Corp., Madison, WI).  $\kappa$ B-LUC (34), containing five tandem repeats of an NF- $\kappa$ B binding site from the *IL-2R $\alpha$*  gene, was kindly provided by Dr. J. Fujisawa (Kansai Medical University, Osaka, Japan). Plasmids pH2Rneo and pH2R40M, containing Tax, have been described previously (35). Plasmids containing wild-type Tax (p $\beta$ MT-2Tax) and a mutant Tax gene (p $\beta$ TaxM22), under the control of a  $\beta$ -actin promoter and its control plasmid (pH BAPr-1-neo), have been described elsewhere (36, 37). Wild-type Tax encoded in p $\beta$ MT-2Tax is effective at activating NF- $\kappa$ B, CAR $\gamma$ , and CRE sites. On the other hand, the Tax mutant encoded by p $\beta$ TaxM22 can activate CAR $\gamma$  and CRE sites but not NF- $\kappa$ B (38). I $\kappa$ B $\alpha$  $\Delta$ N (39) and I $\kappa$ B $\beta$  $\Delta$ N (40; kindly provided by Dr. D. W. Ballard, Vanderbilt University School of Medicine, Nashville, TN) are deletion mutants of I $\kappa$ B $\alpha$  and I $\kappa$ B $\beta$  lacking the NH<sub>2</sub>-terminal 36 amino acids and 23 amino acids, respectively. The kinase-deficient K44M IKK $\alpha$ , K44A IKK $\beta$ , and KK429/430AA NIK mutants have been described previously (21).

**Cell Transfection and LUC Assays.** Transfections were performed by electroporation (41). In all cases, a renilla LUC expression vector, pRL-TK (Toyo Ink Co., Tokyo, Japan), was cotransfected to correct for transfection efficiency. After 24 h of incubation, transfected cells were lysed in lysis reagent (Toyo Ink Co.), and LUC activity was measured according to the protocol provided by the manufacturer. Each assay was independently repeated at least three times.

**EMSA.** NF- $\kappa$ B binding activity to  $\kappa$ B elements was examined by EMSA as described previously (42). In brief, 5  $\mu$ g of nuclear extracts were preincubated in a binding buffer containing 1  $\mu$ g of poly(deoxyinosinic-deoxycytidylic acid). They were then incubated with  $\sim$ 50,000 cpm of  $\alpha$ -<sup>32</sup>P-labeled oligonucleotide probes containing  $\kappa$ B elements for 15 min at room temperature. The DNA-protein complexes were separated on a 4% polyacrylamide gel and visualized by autoradiography. To examine the specificity of the  $\kappa$ B element

probes, unlabeled competitor oligonucleotides were preincubated with nuclear extracts for 15 min before incubation with probes. The probes or competitors used were prepared by annealing the sense and antisense synthetic oligonucleotides as follows: NF- $\kappa$ B element A1 in the *MCP-1* gene, 5'-gatcGATCTGGGAACTTCCAAAGC-3'; A1 mutant (MA1), 5'-gatcGATCTaGaAACTTCCAAAGC-3'; NF- $\kappa$ B element A2 in the *MCP-1* gene, 5'-gatcAGAGTGGGAATTTCCACTCA-3'; A2 mutant (MA2), 5'-gatcA-GAGTGGGAATTcggACTCA-3'; and a typical NF- $\kappa$ B element from the *IL-2R $\alpha$*  gene, 5'-gatcCGGCAGGGGAATCTCCCTCTC-3'. Underlined sequences represent the NF- $\kappa$ B binding site, and mutations are indicated in lowercase. To identify NF- $\kappa$ B/Rel proteins in the DNA-protein complex revealed by EMSA, antibodies specific for various NF- $\kappa$ B/Rel family proteins, including RelA/p65, p50, c-Rel, and NF- $\kappa$ B2 p52 (Santa Cruz Biotechnology, Santa Cruz, CA), were used to elicit a supershift and/or to inhibit DNA-protein complex formation. These antibodies were incubated with the nuclear extracts for 45 min at room temperature, before incubation with radiolabeled probes.

## RESULTS

**Constitutive Expression of MCP-1 mRNA in T-Cell Lines Infected with HTLV-I.** To determine whether MCP-1 expression in T cells correlates with HTLV-I infection, MCP-1 mRNA levels from four HTLV-I-infected and three uninfected human T-cell lines were assessed by RT-PCR using MCP-1-specific primers. Expression of HTLV-I mRNA was confirmed in all four HTLV-I-infected T-cell lines by Northern blot analysis. The MCP-1 transcript was detected




Fig. 1. Determination of the expression of HTLV-I mRNA by Northern blot analysis and MCP-1 mRNA by RT-PCR analysis in various HTLV-I-infected and uninfected human T-cell lines. Total RNA samples were prepared from the indicated T-cell lines. Predominant 2.1-, 4.2-, and 8.5-kb HTLV-I mRNA species were detected in OMT, C5/MJ, MT-2, and HPB-ATL-O cell lines (Lanes 4–7). Glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) and  $\beta$ -actin expression served as controls.




Fig. 2. Detection of MCP-1 mRNA in leukemic cells obtained from ATL patients by RT-PCR analysis. Lane 1, normal PBMCs RNA; Lanes 2-7, PBMCs RNA samples from patients with ATL. Bottom, ethidium bromide staining of the RT-PCR performed with  $\beta$ -actin primers. Arrows, position of the specifically amplified DNA.




Fig. 3. Induction kinetics of the *MCP-1* gene in JPX-9 cells treated with  $\text{CdCl}_2$ . Total RNA samples were prepared from  $\text{CdCl}_2$ -treated JPX-9 cells at the indicated time points. The expression of Tax and MCP-1 in the extracted RNA was analyzed by Northern blot and RT-PCR analysis, respectively.

strongly in all four HTLV-I-infected cell lines (Fig. 1, Lanes 4-7), whereas it was hardly detectable in the uninfected lines (Fig. 1, Lanes 1-3).  $\beta$ -Actin served as the internal control for each sample. This result demonstrates that the *MCP-1* gene is constitutively expressed in HTLV-I-infected T-cell lines.

**Expression of MCP-1 mRNA in Cells Derived from ATL Patients.** Expression of the *MCP-1* gene in leukemic cells derived from patients with ATL was assessed by RT-PCR. In all cases, we observed significant expression of MCP-1 mRNA (Fig. 2), indicating that this gene is up-regulated in cells derived from ATL patients. In contrast, MCP-1 was hardly expressed in PBMCs from normal donors.

**Tax Induces Expression of the *MCP-1* Gene.** Because HTLV-I encodes a strong transcriptional transactivator, Tax, implicated previously in deregulation of host genes, we strongly suggest that Tax was up-regulating *MCP-1* gene transcription. To test whether Tax transactivates the *MCP-1* gene, we next used the inducible Jurkat Tax transfectant, JPX-9, which generates Tax after the addition of  $\text{CdCl}_2$  (28). The level of expression of Tax mRNA in these cells was determined by Northern blot analysis, and expression of the *MCP-1* gene was assayed by RT-PCR (Fig. 3). The addition of  $\text{CdCl}_2$  ( $20 \mu\text{M}$ ) to the culture medium of JPX-9 cells induced the expression of Tax within 5 h, which persisted until 72 h after treatment. A concomitant increase in the expression of MCP-1, within 24 h of treatment with  $\text{CdCl}_2$ , was observed in JPX-9 cells. This increase in MCP-1 mRNA levels was further enhanced 72 h after the treatment. The induction of MCP-1 was attributable to Tax but not by  $\text{CdCl}_2$  treatment, because it was not observed in JPX-9/M expressing the nonfunctional Tax protein after treatment with  $\text{CdCl}_2$  (data not shown). These results indicate that Tax alone is capable of causing elevated expression of the *MCP-1* gene in Jurkat T cells.

**Elevated MCP-1 Levels in Culture Supernatants from HTLV-I-infected T Cells.** We next measured production of MCP-1 in the culture supernatants from HTLV-I-infected and uninfected T-cell lines by ELISA. As shown in Fig. 4A, MCP-1 was produced at low





Fig. 4. A, measurements of MCP-1 secreted in the culture supernatants of human T-cell lines by ELISA. The indicated cell lines were plated at  $5 \times 10^5/\text{ml}$ , and culture supernatants were collected after 72 h. B, induction of MCP-1 in JPX-9 cells after  $\text{CdCl}_2$  induced Tax expression. JPX-9 cells inoculated at  $5 \times 10^5/\text{ml}$  were treated with or without  $20 \mu\text{M}$   $\text{CdCl}_2$  for the indicated durations. MCP-1 secreted in the culture supernatants was quantified by using ELISA. Bars, SD.

Fig. 5. Transactivation of the MCP-1 promoter by wild-type and mutant Tax. Jurkat cells were cotransfected with 0.2  $\mu$ g of either pGLM-ENH or pGLM-PRM and with 5  $\mu$ g of either a wild-type (WT) or mutant (M22) Tax expression vector and 0.4  $\mu$ g of pRL-TK as an internal control. LUC activities were monitored 24 h later. The results correspond to the means of three individual transfections and are expressed as fold induction relative to the basal level measured in cells transfected with the empty vector (pH $\beta$ APr-1-neo); bars, SD. For comparison, data showing the inducibility of  $\kappa$ B ( $\kappa$ B-LUC) and HTLV-I LTR ( $LTR-LUC$ ) reporter plasmids by Tax and M22 Tax have been added.



levels by OMT cells and at very high levels by C5/MJ, MT-2, and HPB-ATL-O. MCP-1 was not produced in uninfected cell lines. MCP-1, thus, was not only expressed but also secreted by HTLV-I-infected T-cell lines. Furthermore, we measured production of MCP-1 in culture supernatants of JPX-9 with or without CdCl<sub>2</sub> treatment (Fig. 4B). Thus, consistent with the ability of Tax to induce the transcription of the *MCP-1* gene, the actual MCP-1 chemokine can be produced and secreted by Tax-expressing cells.


**Transactivation of the MCP-1 Promoter by Tax.** To examine whether the MCP-1 promoter/enhancer responds to Tax, we cotransfected Tax together with LUC reporters under the control of the MCP-1 5' regulatory sequences. Structural features of the human MCP-1 promoter have been described recently (33, 43, 44). Although basal promoter activity is dependent on a proximal promoter region containing an SP-1 site, cytokine-inducible promoter activity is mainly mediated by a distal enhancer region (Fig. 7). Two NF- $\kappa$ B binding sites (A1 and A2), which are crucial for enhancer activity, have been identified in the distal enhancer region (33, 43, 44). Therefore, we used an MCP-1 promoter/enhancer LUC construct, pGLM-ENH, containing the enhancer (between -2742 and -2513) and promoter regions (between -107 and +60) of the human MCP-1 promoter to test for Tax responsiveness [Fig. 5 and see Fig. 7 and Ueda *et al.* (33) for details]. As shown in Fig. 5, wild-type Tax caused an 11-fold stimulation of the pGLM-ENH reporter construct in Jurkat cells. Because the pGLM-PRM reporter, containing only the proximal MCP-1 promoter region, was not responsive to Tax, we conclude that the Tax-responsive target sites are localized in the MCP-1 distal enhancer. Importantly, the Tax M22 plasmid, which is defective for NF- $\kappa$ B activation, failed to activate pGLM-ENH (Fig. 5). This mutant of Tax maintained the ability to transactivate the HTLV-I LTR (Fig.

5). These results indicated that Tax most likely activates the MCP-1 distal enhancer through the NF- $\kappa$ B pathway.

**Tax-mediated Activation of the MCP-1 Distal Enhancer Can Be Blocked by Dominant Interfering Signaling Components of the NF- $\kappa$ B Pathway.** We next examined whether blocking of the NF- $\kappa$ B pathway can affect Tax-induced transactivation of the MCP-1 distal enhancer by using dominant interfering mutants of I $\kappa$ B $\alpha$  and I $\kappa$ B $\beta$  and kinase-deficient mutants of IKK $\alpha$ , IKK $\beta$ , and NIK. As controls for these experiments, the effects of these mutants on Tax-mediated activation of the HTLV-I LTR and a multimerized NF- $\kappa$ B site from the IL-2R $\alpha$  promoter ( $\kappa$ B-LUC) were evaluated in parallel. Consistent with previous findings (20, 21), transfection of these mutant vectors resulted in inhibition of Tax activation of  $\kappa$ B-LUC activity (Fig. 6). In contrast, these mutants produced no significant inhibition of Tax-induced HTLV-I LTR LUC activity. Finally, these mutants were cotransfected along with the wild-type Tax plasmid and the pGLM-ENH. As shown in Fig. 6, the elevated LUC activity in response to Tax was markedly suppressed by cotransfection with the dominant interfering mutants. These results confirmed that the NF- $\kappa$ B pathway was involved in Tax-induced transactivation of the MCP-1 distal enhancer.

**Cooperation between the A1 and A2 Sites of the MCP-1 Distal Enhancer in Tax-induced Activation.** Two NF- $\kappa$ B binding sites (A1 and A2) have been identified in the distal enhancer region of the *MCP-1* gene, which are crucial for enhancer activity (33, 43, 44). To investigate the role of the A1 site and a possible cooperation with the A2 site in Tax transactivation, the sequences of the A1 and the A2 sites were mutated (Fig. 7). The A1 and A2 mutant reporter constructs were cotransfected along with the Tax expression plasmid. As shown in Fig. 7, Tax-induced LUC activity was significantly reduced by

Fig. 6. Functional effects of I $\kappa$ B $\alpha$  and I $\kappa$ B $\beta$  mutants and kinase-deficient IKK $\alpha$ , IKK $\beta$ , and NIK mutants on HTLV-I Tax induction of the MCP-1 distal enhancer in Jurkat cells. Cells were transfected with 5  $\mu$ g of Tax (pH2R40M), 5  $\mu$ g of the I $\kappa$ B  $\alpha$  mutant I $\kappa$ B $\alpha$  $\Delta$ N, I $\kappa$ B $\alpha$  mutant I $\kappa$ B $\beta$  $\Delta$ N, the K44M mutant of IKK $\alpha$ , the K44A mutant of IKK  $\beta$ , or the kinase-deficient KK429/430AA mutant of NIK, and 0.2  $\mu$ g of pGLM-ENH, the  $\kappa$ B-LUC, or the HTLV-I LTR LUC reporter plasmid. Each transfection also contained 0.4  $\mu$ g of pRL-TK and was supplemented to 5  $\mu$ g with the parental pCMV4 vector. LUC activity is presented as fold induction relative to the basal level measured in cells transfected with pH2Rneo. The values are means from three independent experiments; bars, SD.






Fig. 7. Cooperation between the A1 and A2 sites of the MCP-1 distal enhancer in Tax-induced *MCP-1* gene transcription. Schematic representation of the MCP-1 reporter constructs. ■, proximal promoter region; □, distal enhancer region of the *MCP-1* gene. The A1 and A2 sites of the MCP-1 distal enhancer region were mutated (X) in some of the constructs. These constructs were transfected into Jurkat cells, and LUC activities were compared. Cells were cotransfected with either pH2R40M (+Tax) or the empty vector pH2Rneo. Bars, SD.

mutation in either the A1 or A2 sequences, indicating that Tax transactivation of the MCP-1 distal enhancer involves both A1 and A2 sites. These results suggest that both the A1 and the A2 sites are important for Tax-induced *MCP-1* gene transcription.

**Binding of NF- $\kappa$ B/Rel Family Proteins to the A1 and A2  $\kappa$ B Elements of the MCP-1 Distal Enhancer.** We next examined whether NF- $\kappa$ B/Rel family members can actually bind to the putative A1 and A2  $\kappa$ B elements identified in the MCP-1 distal enhancer by EMSA. Synthetic oligonucleotides containing the A1 site (-2640 to -2632 relative to the MCP-1 transcription start site) and the A2 site (-2612 to -2603) of the MCP-1 distal enhancer were used as probes. When the A1 site was used as a probe, a clear shifted band was observed with nuclear extracts from HTLV-I-infected T-cell lines but not with uninfected cell nuclear extracts (Fig. 8A, Lanes 1-7). This shifted complex was specific to the A1 fragment because complex formation was competed away by addition of excess cold probe and the typical NF- $\kappa$ B sequence of the IL-2R $\alpha$  enhancer and also by probe A2 but not by a mutant sequence of A1 (Fig. 8B, Lanes 1-5). The A2 probe essentially showed the same pattern of complex formation as probe A1 (Fig. 8A, Lanes 8-14, and Fig. 8B, Lanes 6-10). To identify which NF- $\kappa$ B/Rel family members were binding to the A1 and A2 elements of the MCP-1 distal enhancer, we performed EMSA using antibodies specific for members of the NF- $\kappa$ B/Rel family. Supershifts were seen with anti-p65 and anti-p50 antibodies in complexes formed with both probes A1 and A2, illustrating that these complexes contain the p50 and p65 subunits of NF- $\kappa$ B (Fig. 8C).

To examine which NF- $\kappa$ B/Rel family members Tax was inducing to associate with the A1 and A2 elements of the MCP-1 distal enhancer, we performed an EMSA analysis using nuclear extracts from the Tax-inducible T-cell line, JPX-9. Induction of Tax expression resulted in induction of complex formation with probes A1 and A2 (Fig. 9A). This binding was competed away by the typical NF- $\kappa$ B sequence derived from the IL-2R $\alpha$  enhancer but not by mutant sequences of the A1 and A2 elements (Fig. 9B). The Tax-induced complexes identified by the A1 and A2 probes were also characterized. These complexes were supershifted by the addition of anti-p50 or anti-p65 antibodies (Fig. 9C). Thus, Tax induces *MCP-1* gene expression, at least in part, through the induced binding of the p50 and p65 NF- $\kappa$ B/Rel family members to the A1 and A2 elements of the MCP-1 distal enhancer.

## DISCUSSION

This study has revealed that HTLV-I infection of T cells leads to a marked increase in the transcription of the *MCP-1* gene resulting from transactivation by the viral Tax protein. Consistent with this finding, HTLV-I-infected and Tax-expressing T cells secrete the MCP-1 chemokine. MCP-1 is induced by proinflammatory cytokines and growth factors (9, 10). Molecular studies from a number of laboratories have identified some of the *cis*-regulatory elements and *trans*-acting factors involved in this response. Two NF- $\kappa$ B binding sites (A1 and A2) located ~2.6 kb from the transcription initiation site appear to function as the critical elements in MCP-1 induction in response to IL-1 $\beta$  and tumor necrosis factor- $\alpha$  (33, 43, 44). Additional elements in proximity of these  $\kappa$ B sites (45, 46) and a 7-bp response element situated with the 3' untranslated region of the MCP-1 transcript (47) are also involved in the regulation of *MCP-1* gene expression, in response to platelet-derived growth factor. Thus, this distal group of




Fig. 8. Binding of nuclear proteins from HTLV-I-infected T cells to the A1 and A2 probes derived from the MCP-1 distal enhancer. A, nuclear extracts were prepared from HTLV-I-infected (OMT, C5/MJ, MT-2, and HPB-ATL-O) and uninfected (Jurkat, MOLT-4, and CCRF-CEM) T cells and incubated with  $^{32}$ P-labeled A1 (Lanes 1-7) and A2 probes (Lanes 8-14). B, sequence specificity of NF- $\kappa$ B binding activity in HPB-ATL-O cells. Competition assays were performed with 100-fold excess amounts of each specific competitor oligonucleotide. C, characterization of NF- $\kappa$ B/Rel proteins that bound to the A1 and A2  $\kappa$ B sites of the *MCP-1* gene. Nuclear extracts from HPB-ATL-O cells were preincubated with appropriate antibodies before addition of  $^{32}$ P-labeled probes.




Fig. 9. Tax-induced NF- $\kappa$ B binding activity to the A1 and A2 elements of the MCP-1 distal enhancer. *A*, nuclear extracts from JPX-9 cells, treated with or without CdCl<sub>2</sub> (20  $\mu$ M) for the indicated time periods, were mixed with  $\kappa$ B elements A1 (Lanes 1–6) and A2 (Lanes 7–12). *B*, nuclear extracts from JPX-9 cells treated with CdCl<sub>2</sub> for 48 h were mixed with labeled probes A1 (Lanes 1–5) and A2 (Lanes 6–10) in the absence or presence of 100-fold excess amounts of each specific competitor oligonucleotide. *C*, JPX-9 nuclear extracts obtained after 48 h of CdCl<sub>2</sub> treatment were incubated with the indicated antibodies, before addition of the labeled probes A1 (Lanes 1–5) and A2 (Lanes 6–10).

regulatory elements plays a significant role in *MCP-1* gene transcription. Tax is known to activate NF- $\kappa$ B by activating IKKs and other related molecules (18–24). Our finding that a Tax mutant defective in NF- $\kappa$ B activation (M22) was unable to transactivate the MCP-1 distal enhancer together with the observation that dominant-negative I $\kappa$ Bs, IKKs, and NIK expression plasmids blocked Tax transactivation of this same enhancer allowed us to conclude that the activation of the *MCP-1* gene by the HTLV-I Tax protein involves primarily the NF- $\kappa$ B pathway. The observation that binding of NF- $\kappa$ B transcription factors to both A1 and A2 sites and reduction of activity of the MCP-1 promoter by mutation in either element is consistent with Tax requiring the NF- $\kappa$ B pathway to transactivate the MCP-1 promoter/enhancer.

Pathological roles for MCP-1 in HTLV-I-associated diseases are not known. MCP-1 is mainly produced by monocytes and not by T cells. However, we demonstrated that aberrant MCP-1 expression was restricted to T cells expressing HTLV-I. We, therefore, speculated that deregulated MCP-1 expression in HTLV-I-infected cells may represent an important pathogenic determinant in HTLV-I-associated dis-

eases. One of the characteristic features of HTLV-I-associated diseases is prominent tissue infiltration of lymphoid cells. For example, ATL is frequently accompanied by lymphadenopathy, hepatosplenomegaly, and skin lesions. Similarly, major pathological changes in HAM/TSP are marked infiltration of HTLV-I-infected T cells around small vessels in the spinal cord. MCP-1 has been considered as an important mediator that specifically stimulates directional migration of T cells and monocytes/macrophages. MCP-1 has also been shown to modulate leukocyte adhesion molecule expression and other leukocyte functions that are necessary for leukocytes to leave the circulation and infiltrate tissues. Aberrant production of MCP-1 by leukemic cells in ATL or HTLV-I-infected T-cells in HAM/TSP may promote influx of lymphoid cells into the affected tissues.

In summary, this study allowed identification of mechanisms by which MCP-1 expression is deregulated by the pathogenic human retrovirus HTLV-I. Additional studies of the potential function of MCP-1 in HTLV-I-infected T cells may provide important insights into the pathogenesis of HTLV-I infection.

#### ACKNOWLEDGMENTS

We thank Drs. M. Hatanaka, K. Matsumoto, I. Futsuki, J. Fujisawa, and D. W. Ballard for providing pH2Rneo, pH2R40M; p $\beta$ APr-1-neo, p $\beta$  MT-2Tax, p $\beta$ TaxM22; LTR-LUC;  $\kappa$ B-LUC; and I $\kappa$ B $\alpha$  $\Delta$ N, I $\kappa$ B $\beta$  $\Delta$ N, respectively. We also thank Dr. M. Nakamura for providing JPX-9 and pPX-9/M and Fujisaki Cell Center, Hayashibara Biochemical Laboratories, Inc. (Okayama, Japan) for providing Jurkat and C5/MJ cell lines. We are grateful to M. Yamamoto and M. Sasaki for excellent technical assistance.

#### REFERENCES

- Poiesz, B. J., Ruscetti, F. W., Gazdar, A. F., Bunn, P. A., Minna, J. D., and Gallo, R. C. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. *Proc. Natl. Acad. Sci. USA*, *77*: 7415–7419, 1980.
- Yoshida, M., Miyoshi, I., and Hinuma, Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. *Proc. Natl. Acad. Sci. USA*, *79*: 2031–2035, 1982.
- Gassain, A., Barin, F., Vernant, J. C., Gout, O., Maurs, L., Calender, A., and de The, G. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. *Lancet*, *2*: 407–410, 1985.
- Osame, M., Usuku, K., Izumo, S., Ijichi, N., Amitani, H., Igata, A., Matsumoto, M., and Tara, M. HTLV-I associated myelopathy, a new clinical entity. *Lancet*, *1*: 1031–1032, 1986.
- Nishioka, K., Maruyama, I., Sato, K., Kitajima, I., Nakajima, Y., and Osame, M. Chronic inflammatory arthropathy associated with HTLV-I. *Lancet*, *1*: 441, 1989.
- Mochizuki, M., Watanabe, T., Yamaguchi, K., Takatsuki, K., Yoshimura, K., Shiro, M., Nakashima, S., Mori, S., Araki, S., and Miyata, N. HTLV-I uveitis: a distinct clinical entity caused by HTLV-I. *Jpn. J. Cancer Res.*, *83*: 236–239, 1992.
- Vernant, J.-C., Buisson, G., Magdeleine, J., De Thore, J., Jouannelle, A., Neisson-Vernant, C., and Monplaisir, N. T-lymphocyte alveolitis, tropical spastic paresis, and Sjögren syndrome. *Lancet*, *1*: 177, 1988.
- Baggiolini, M., Dewald, B., and Moser, B. Human chemokines: an update. *Annu. Rev. Immunol.*, *15*: 675–705, 1997.
- Mantovani, A., Bussolino, F., and Introna, M. Cytokine regulation of endothelial cell function: from molecular level to the bedside. *Immunol. Today*, *18*: 231–240, 1997.
- Strieter, R. M., and Kunkel, S. L. The immunopathology of chemotactic cytokines. *Adv. Exp. Med. Biol.*, *351*: 19–28, 1993.
- Randolph, G. J., and Furie, M. B. A soluble gradient of endogenous monocyte chemoattractant protein-1 promotes the transendothelial migration of monocytes *in vitro*. *J. Immunol.*, *155*: 3610–3618, 1995.
- Carr, M. W., Roth, S. J., Luther, E., Rose, S. S., and Springer, T. A. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. *Proc. Natl. Acad. Sci. USA*, *91*: 3652–3656, 1994.
- Rand, M. L., Warren, J. S., Mansour, M. K., Newman, W., and Ringler, D. J. Inhibition of T cell recruitment and cutaneous delayed-type hypersensitivity-induced inflammation with antibodies to monocyte chemoattractant protein-1. *Am. J. Pathol.*, *148*: 855–864, 1996.
- Umehara, F., Izumo, S., Takeya, M., Takahashi, K., Sato, E., and Osame, M. Expression of adhesion molecules and monocyte chemoattractant protein-1 (MCP-1) in the spinal cord lesions in HTLV-I-associated myelopathy. *Acta Neuropathol.*, *91*: 343–350, 1996.
- Zhao, L.-J., and Giam, C.-Z. Human T-cell lymphotropic virus type I (HTLV-I) transcriptional activator, Tax, enhances CREB binding to HTLV-I 21-base-pair repeats by protein-protein interaction. *Proc. Natl. Acad. Sci. USA*, *89*: 7070–7074, 1992.

16. Ballard, D. W., Bohnlein, E., Lowenthal, J. W., Wano, Y., Franza, B. R., and Greene, W. C. HTLV-I tax induces cellular proteins that activate the  $\kappa$ B element in the IL-2 receptor  $\alpha$  gene. *Science* (Washington DC), *241*: 1652–1655, 1988.
17. Fujii, M., Tsuchiya, H., Chuho, T., Akizawa, T., and Seiki M. Interaction of HTLV-I Tax1 with p67<sup>SRF</sup> causes the aberrant induction of cellular immediate early genes through CArG boxes. *Genes Dev.*, *6*: 2066–2076, 1992.
18. Yin, M.-J., Christerson, L. B., Yamamoto, Y., Kwak, Y.-T., Xu, S., Mercurio, F., Barbosa, M., Cobb, M. H., and Gaynor, R. B. HTLV-I Tax protein binds to MEKK1 to stimulate I $\kappa$ B kinase activity and NF- $\kappa$ B activation. *Cell*, *93*: 875–884, 1998.
19. Chu, Z.-L., DiDonato, J. A., Hawiger, J., and Ballard, D. W. The Tax oncoprotein of human T-cell leukemia virus Type I associates with and persistently activates I $\kappa$ B kinases containing IKK $\alpha$  and IKK $\beta$ . *J. Biol. Chem.*, *273*: 15891–15894, 1998.
20. Uhlik, M., Good, L., Xiao, G., Harhaj, E. W., Zandi, E., Karin, M., and Sun, S.-C. NF- $\kappa$ B-inducing kinase and I $\kappa$ B kinase participate in human T-cell leukemia virus I Tax-mediated NF- $\kappa$ B activation. *J. Biol. Chem.*, *273*: 21132–21136, 1998.
21. Geleziunas, R., Ferrell, S., Lin, X., Mu, Y., Cunningham, E. T., Jr., Grant, M., Connelly, M. A., Hambor, J. E., Marcu, K. B., and Greene, W. C. Human T-cell leukemia virus type I Tax induction of NF- $\kappa$ B involves activation of the I $\kappa$ B kinase  $\alpha$  (IKK $\alpha$ ) and IKK $\beta$  cellular kinases. *Mol. Cell Biol.*, *18*: 5157–5165, 1998.
22. Yamaoka, S., Courtois, G., Bessia, C., Whiteside, S. T., Weil, R., Agou, F., Kirk, H. E., Kay, R. J., and Israel, A. Complementation cloning of NEMO, a component of the I $\kappa$ B kinase complex essential for NF- $\kappa$ B activation. *Cell*, *93*: 1231–1240, 1998.
23. Chu, Z.-L., Shin, Y.-A., Yang, J.-M., DiDonato, J. A., and Ballard, D. W. IKK $\beta$  mediates the interaction of cellular I $\kappa$ B kinases with the Tax transforming protein of human T cell leukemia virus type I. *J. Biol. Chem.*, *274*: 15297–15300, 1999.
24. Jin, D.-Y., Giordano, V., Kibler, K. V., Nakano, H., and Jeang, K.-T. Role of adapter function in oncoprotein-mediated activation of NF- $\kappa$ B. Human T-cell leukemia virus type I Tax interacts directly with I $\kappa$ B kinase  $\beta$ . *J. Biol. Chem.*, *274*: 17402–17405, 1999.
25. Yamada, Y., Sugawara, K., Hata, T., Tsuruta, K., Moriuchi, R., Maeda, T., Atogami, S., Murata, K., Fujimoto, K., Kohno, T., Tsukasaki, K., Tomonaga, M., Hirakata, Y., and Kamihira, S. Interleukin-15 (IL-15) can replace the IL-2 signal in IL-2-dependent adult T-cell leukemia (ATL) cell lines: expression of IL-15 receptor  $\alpha$  on ATL cells. *Blood*, *91*: 4265–4272, 1998.
26. Popovic, M., Sarin, P. S., Robert-Guroff, M., Kalyanaraman, V. S., Mann, D., Minowada, J., and Gallo, R. C. Isolation and transmission of human retrovirus (human T-cell leukemia virus). *Science* (Washington DC), *219*: 856–859, 1983.
27. Miyoshi, I., Kubonishi, I., Yoshimoto, S., Akagi, T., Ohtsuki, Y., Shiraishi, Y., Nagata, K., and Hinuma, Y. Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. *Nature* (Lond.), *294*: 770–771, 1981.
28. Nagata, K., Ohtani, K., Nakamura, M., and Sugamura, K. Activation of endogenous *c-fos* proto-oncogene expression by human T-cell leukemia virus type I-encoded p40<sup>tax</sup> protein in the human T-cell line, Jurkat. *J. Virol.*, *63*: 3220–3226, 1989.
29. Ohtani, K., Tsujimoto, A., Tsukahara, T., Numata, N., Miura, S., Sugamura, K., and Nakamura, M. Molecular mechanisms of promoter regulation of the *gp34* gene that is *trans*-activated by an oncoprotein Tax of human T cell leukemia virus type I. *J. Biol. Chem.*, *273*: 14119–14129, 1998.
30. Kasai, K., Banba, N., Motohashi, S., Hattori, Y., Manaka, K., and Shimoda, S. I. Expression of monocyte chemoattractant protein-1 mRNA and protein in cultured human thyrocytes. *FEBS Lett.*, *394*: 137–140, 1996.
31. Seiki, M., Hikikoshi, A., Taniguchi, T., and Yoshida, M. Expression of the *pX* gene of HTLV-I: general splicing mechanism in the HTLV family. *Science* (Washington DC), *228*: 1532–1534, 1985.
32. Benham, F. J., Hodgkinson, S., and Davies, K. E. A glyceraldehyde-3-phosphate dehydrogenase pseudogene on the short arm of the human X chromosomes defines a multigene family. *EMBO J.*, *3*: 2635–2640, 1984.
33. Ueda, A., Ishigatsubo, Y., Okubo, T., and Yoshimura, T. Transcriptional regulation of the human monocyte chemoattractant protein-1 gene. Cooperation of two NF- $\kappa$ B sites and NF- $\kappa$ B/Rel subunit specificity. *J. Biol. Chem.*, *272*: 31092–31099, 1997.
34. Suzuki, T., Hirai, H., Murakami, T., and Yoshida, M. Tax protein of HTLV-I destabilizes the complexes of NF- $\kappa$ B and I $\kappa$ B- $\alpha$  and induces nuclear translocation of NF- $\kappa$ B for transcriptional activation. *Oncogene*, *10*: 1199–1207, 1995.
35. Tanaka, A., Takahashi, C., Yamaoka, S., Nosaka, T., Maki, M., and Hatanaka, M. Oncogenic transformation by the *tax* gene of human T-cell leukemia virus type I *in vitro*. *Proc. Natl. Acad. Sci. USA*, *87*: 1071–1075, 1990.
36. Gunning, P., Leavitt, J., Muscat, G., Ng, S. Y., and Kedes, L. A human  $\beta$ -actin expression vector system directs high-level accumulation of antisense transcripts. *Proc. Natl. Acad. Sci. USA*, *84*: 4831–4835, 1987.
37. Matsumoto, K., Shibata, H., Fujisawa, J., Inoue, H., Hakura, A., Tsukahara, T., and Fujii, M. Human T-cell leukemia virus type I Tax protein transforms rat fibroblasts via two distinct pathways. *J. Virol.*, *71*: 4445–4451, 1997.
38. Smith, M. R., and Greene, W. C. Identification of HTLV-I tax *trans*-activator mutants exhibiting novel transcriptional phenotypes [published errata appear in *Genes Dev.*, *5*: 150, 1991 and *Genes Dev.*, *9*: 2324, 1995]. *Genes Dev.*, *4*: 1875–1885, 1990.
39. Brockman, J. A., Scherer, D. C., McKinsey, T. A., Hall, S. M., Qi, X., Lee, W. Y., and Ballard, D. W. Coupling of a signal response domain in I $\kappa$ B $\alpha$  to multiple pathways for NF- $\kappa$ B activation. *Mol. Cell Biol.*, *15*: 2809–2818, 1995.
40. McKinsey, T. A., Brockman, J. A., Scherer, D. C., Al-Murrani, S. W., Green, P. L., and Ballard, D. W. Inactivation of I $\kappa$ B $\beta$  by the Tax protein of human T-cell leukemia virus type I: a potential mechanism for constitutive induction of NF- $\kappa$ B. *Mol. Cell Biol.*, *16*: 2083–2090, 1996.
41. Mori, N., and Prager, D. Transactivation of the interleukin-1 $\alpha$  promoter by human T-cell leukemia virus type I and type II Tax proteins. *Blood*, *87*: 3410–3417, 1996.
42. Mori, N., Fujii, M., Ikeda, S., Yamada, Y., Tomonaga, M., Ballard, D. W., and Yamamoto, N. Constitutive activation of NF- $\kappa$ B in primary adult T-cell leukemia cells. *Blood*, *93*: 2360–2368, 1999.
43. Ueda, A., Okuda, K., Ohno, S., Shirai, A., Igarashi, T., Matsunaga, K., Fukushima, J., Kawamoto, S., Ishigatsubo, Y., and Okubo, T. NF- $\kappa$ B and Sp1 regulate transcription of the human monocyte chemoattractant protein-1 gene. *J. Immunol.*, *153*: 2052–2063, 1994.
44. Ping, D., Jones, P. L., and Boss, J. M. TNF regulates the *in vivo* occupancy of both distal and proximal regulatory regions of the *MCP-1/JE* gene. *Immunity*, *4*: 455–469, 1996.
45. Freter, R. R., Alberta, J. A., Lam, K. K., and Stiles, C. D. A new platelet-derived growth factor-regulated genomic element which binds a serine/threonine phosphoprotein mediates induction of the slow immediate-early gene *MCP-1*. *Mol. Cell Biol.*, *15*: 315–325, 1995.
46. Freter, R. R., Alberta, J. A., Hwang, G. Y., Wrentmore, A. L., and Stiles, C. D. Platelet-derived growth factor induction of the immediate-early gene *MCP-1* is mediated by NF- $\kappa$ B and a 90-kDa phosphoprotein coactivator. *J. Biol. Chem.*, *271*: 17417–17424, 1996.
47. Freter, R. R., Irminger, J. C., Porter, J. A., Jones, S. D., and Stiles, C. D. A novel 7-nucleotide motif located in 3' untranslated sequences of the immediate-early gene set mediates platelet-derived growth factor induction of the *JE* gene. *Mol. Cell Biol.*, *12*: 5288–5300, 1992.

# Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

## Human T-Cell Leukemia Virus Type I Tax Activates Transcription of the Human Monocyte Chemoattractant Protein-1 Gene through Two Nuclear Factor- $\kappa$ B Sites

Naoki Mori, Atsuhisa Ueda, Shuichi Ikeda, et al.

*Cancer Res* 2000;60:4939-4945.

**Updated version** Access the most recent version of this article at:  
<http://cancerres.aacrjournals.org/content/60/17/4939>

**Cited articles** This article cites 44 articles, 28 of which you can access for free at:  
<http://cancerres.aacrjournals.org/content/60/17/4939.full#ref-list-1>

**Citing articles** This article has been cited by 6 HighWire-hosted articles. Access the articles at:  
<http://cancerres.aacrjournals.org/content/60/17/4939.full#related-urls>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link  
<http://cancerres.aacrjournals.org/content/60/17/4939>.  
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.